Sarcoidosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The sarcoidosis marketed and pipeline drugs assessment reports provides a data-driven overview of the current and future competitive landscape in sarcoidosis therapeutics. Sarcoidosis usually presents with persistent dry cough, eye and skin manifestations, weight loss, fatigue, night sweats, and erythema nodosum. Various factors including infection, genetic predisposition, and environmental factors are involved in the pathology of sarcoidosis. Exposures to insecticides, herbicides, bioaerosols, and agricultural employment are associated with an increased risk for sarcoidosis. An early and accurate diagnosis of sarcoidosis remains challenging because initial presentations may vary, many patients remain asymptomatic, and there is no single reliable diagnostic test.
Which are the key countries by number of clinical trials in the sarcoidosis market?
The key countries by number of clinical trials in the sarcoidosis market are the US, Netherlands, Japan, India, Canada, South Korea, France, Germany, and the UK. The US has the highest number of clinical trials in the sarcoidosis market, followed by the UK.
Sarcoidosis market, by key countries
For more country insights, download a free sample
What are the key phases in the sarcoidosis market?
The key phases in the sarcoidosis market are discovery, pre-clinical, clinical, and IND/CTA filed, phase I, phase II, and phase III. Pre-clinical molecules constitute the majority of the pipeline. R&D activities for the treatment of sarcoidosis are very limited, with a total of only 19 molecules present in the sarcoidosis pipeline. There is only one drug (a synthetic peptide) in the late-stage (Phase III) sarcoidosis pipeline.
Sarcoidosis market, by phases
For more phase insights, download a free sample
Who are the key sponsors in the sarcoidosis market?
The key sponsors in the sarcoidosis market are Galapagos, Celularity Inc, Bio-Innova & Synchron Co, Bellelophron Therapeutics, a Tyr pharma, Araim pharmaceuticals, Amgen, Actelion pharmaceuticals, Novartis AG, Celgene Corp. Celgene is the top sponsor in sarcoidosis clinical research with five clinical trials. After Celgene, the most active sponsor of sarcoidosis clinical trials is Novartis.
Market report scope
Key countries | The US, Netherlands, Japan, India, Canada, South Korea, France, Germany, and The UK. |
Key phases | Discovery, Pre-Clinical, Clinical, And IND/CTA Filed, Phase I, Phase II, and Phase III |
Key sponsors | Galapagos, Celularity Inc, Bio-Innova & Synchron Co, Bellelophron Therapeutics, a Tyr pharma, Araim pharmaceuticals, Amgen, Actelion pharmaceuticals, Novartis AG, Celegene Corp |
Scope
GlobalData’s Sarcoidosis Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- The accompanying Excel file includes the following datasets:
- Marketed products exported from GlobalData’s Pharmaceutical Intelligence Center
- Pipeline-stage products exported from GlobalData’s Pharmaceutical Intelligence Center
- Upcoming catalysts in the sarcoidosis market exported from the Catalyst Calendar on GlobalData’s Pharmaceutical Intelligence Center
- A list of patent expiry dates for sarcoidosis products
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the sarcoidosis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global sarcoidosis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which are the key countries by number of clinical trials in the sarcoidosis market?
The US, Netherlands, Japan, India, Canada, South Korea, France, Germany, and the UK are the key countries by number of clinical trials in the sarcoidosis market.
-
What are the key phases in the sarcoidosis market?
Discovery, pre-clinical, clinical, and IND/CTA filed, phase I, phase II, and phase III are the key phases in the sarcoidosis market.
-
Who are the key sponsors in the sarcoidosis market?
Galapagos, Celularity Inc, Bio-Innova & Synchron Co, Bellelophron Therapeutics, a Tyr pharma, Araim pharmaceuticals, Amgen, Actelion pharmaceuticals, Novartis AG, Celegene Corp are the key sponsors in the sarcoidosis market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.